Compare Cardinal Health Inc (CAH) vs Unilever plc (UL) Price & Performance

Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.

The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.

Unilever (UL) trades at $61.48, down 0.39% on the day, with a bullish technical signal driven by moving averages. The company reported $60.76B in 2024 revenue but missed Q1 and Q2 2025 EPS estimates. Recent news highlights strategic moves including a potential bid for Thorne and a $270M innovation center investment. The stock shows strong profitability with a 18.75% net margin and 53.32% ROE, though valuation ratios like P/E of 20.84 suggest fair pricing amid mixed analyst sentiment.

Outlook remains cautious with near-term earnings misses offset by long-term growth initiatives. Investment appeal hinges on successful integration of acquisitions and margin improvement. Key risks include competitive pressures and macroeconomic volatility. Analysts are divided with 24% buy ratings, reflecting balanced risk-reward at current levels.